Skip to main content

The continuing evolution of GLP-1RAs

On-demand webcast

Don’t miss out on this expert-led webcast on the continuing evolution of glucagon-like peptide-1 receptor agonists, chaired by Professor John Wilding. 

Click here to watch the full webcast now © Springer Healthcare IME

During the webcast, the expert panel will discuss:

  • The importance of early and effective treatment to reduce the risk of complications and avoid clinical inertia.
  • The appropriate use of the different once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) formulations.
  • The next generation, non-injectable GLP-1RAs and the role they will play in the management of type 2 diabetes.

Watch the full webcast now

Target audience

This webcast is suitable for, but not limited to, diabetes specialists, primary care physicians, specialist diabetes nurses, cardiologists, and all other healthcare professionals interested in the treatment of type 2 diabetes.

Learning objectives

Following this webcast, you will be able to:

  1. Discuss the importance of timely treatment of type 2 diabetes and its impact on patient health and outcomes.
  2. Compare the efficacy and safety profiles of once weekly GLP-1RAs.
  3. Explain the next generation of GLP-1RAs including the mode of absorption, mechanism of action, dosing schedule, pharmacokinetic/pharmacodynamic properties, glycemic/weight loss efficacy and safety.



An application has been made to the UEMS EACCME® for CME accreditation of this activity.

Educational grant

This program is made possible thanks to an independent educational grant from Novo Nordisk A/S.

Contact us

Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK